ArticleScientific reports2020
Increasing incidence of group B streptococcus neonatal infections in the Netherlands is associated with clonal expansion of CC17 and CC23.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Global patterns of antibiotic resistance in group BFrontiers in microbiology · 2025Pooled it
- Acquisition of a novel restriction modification system regulates genetic flux and gene expression in the hypervirulent and globally disseminated CC17 lineage of group B Streptococcus.Nucleic acids research · 2026Article
- Group B streptococcal disease in infants 0-3 months in The Netherlands, 1987-2023: a nationwide genomic and epidemiological surveillance study.The Lancet regional health. Europe · 2026Article
- Gene Factors and Serotypes Related to Polysaccharide and Protein-Based Candidate Vaccines AmongCurrent issues in molecular biology · 2026Article
- Antibiotic Prophylaxis and Treatment of Neonatal Group B Streptococcus Disease in the Era of Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- A nationwide study of invasive Streptococcus agalactiae in the Faroe Islands from 2009 to 2024.Scientific reports · 2026Article
- Towards a holistic epidemiology ofFrontiers in bioinformatics · 2026Article
- Whole-genome characterization of neonatal group B Streptococcus infection isolates and contemporaneous maternal colonizing isolates in Southwest China.Frontiers in microbiology · 2026Article
- Genetic Determinants and Clonal Composition of Levofloxacin-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Genomic characterization of group BMicrobial genomics · 2025Article
- Prevalence and Antibiotic Resistance ofLife (Basel, Switzerland) · 2024Article
- Development of bioluminescent Group B streptococcal strains for longitudinal infection studies.Scientific reports · 2024Article
- Revisiting typing systems for group BMicrobial genomics · 2024Article
- Population genomics of Streptococcus mitis in UK and Ireland bloodstream infection and infective endocarditis cases.Nature communications · 2024Article
- Macrolide and lincosamide resistance of Streptococcus agalactiae in pregnant women in Poland.Scientific reports · 2024Article
- Genetic markers associated with host status and clonal expansion of Group B Streptococcus in the Netherlands.Frontiers in microbiology · 2024Article
- Mutational spectra are associated with bacterial niche.Nature communications · 2023Article
- Group BAntibiotics (Basel, Switzerland) · 2023Review
- Comparative Analysis of the Molecular Characteristics of Group BAnnals of laboratory medicine · 2023Article
- Differential Interaction between Invasive Thai Group BMicroorganisms · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
Group B streptococcus (GBS) is the leading cause of neonatal invasive disease worldwide. In the Netherlands incidence of the disease increased despite implementation of preventive guidelines. We describe a genomic analysis of 1345 GBS isolates from neonatal (age 0-89 days) invasive infections in the Netherlands reported between 1987 and 2016. Most isolates clustered into one of five major lineages: CC17 (39%), CC19 (25%), CC23 (18%), CC10 (9%) and CC1 (7%). There was a significant rise in the number of infections due to isolates from CC17 and CC23. Phylogenetic clustering analysis revealed that this was caused by expansion of specific sub-lineages, designated CC17-A1, CC17-A2 and CC23-A1. Dating of phylogenetic trees estimated that these clones diverged in the 1960s/1970s, representing historical rather than recently emerged clones. For CC17-A1 the expansion correlated with acquisition of a new phage, carrying gene encoding a putative cell-surface protein. Representatives of CC17-A1, CC17-A2 and CC23-A1 clones were identified in datasets from other countries demonstrating their global distribution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.